MyoKardia, Inc

119 articles with MyoKardia, Inc

• 

  Top 12 Biotech Companies Hiring Now

  10/6/2020

  According to BioSpace research, 69% of biotech professionals feel they are on the verge of job burnout. Do you fall into that 69%? Is it time for a new job? Check out the top companies who are looking for candidates like you right now!

• Bristol Myers Squibb to Acquire MyoKardia for $13.1 Billion in Cash

  10/5/2020

  Mavacamten Is a Potential First-in-Class Medicine with Compelling Data in the Treatment of Patients with Symptomatic Obstructive Hypertrophic Cardiomyopathy

• 

  BMS Strengthens Cardiovascular Business with $13.1 Billion MyoKardia Buyout

  10/5/2020

  Only a year after buying cancer specialist Celgene for $74 billion, Bristol Myers Squibb announced it is buying cardiology company MyoKardia for about $13.1 billion. The deal is expected to close before the end of the year.

• MyoKardia Doses First Patient in Phase 2 Clinical Trial of Danicamtiv in Genetic Dilated Cardiomyopathy

  9/9/2020

  MyoKardia, Inc. (Nasdaq: MYOK) today announced that the first patient has been dosed in the company’s Phase 2 clinical trial of danicamtiv (formerly MYK-491) in people with primary dilated cardiomyopathy (DCM) thought to be caused by genetic mutations of the sarcomere.

• MyoKardia to Participate in September Investor Conferences

  9/2/2020

  MyoKardia, Inc. (Nasdaq: MYOK) today announced its participation in the following upcoming investor conferences: Citi’s 15th Annual BioPharma Virtual Conference on Wednesday, September 9, 2020. Taylor Harris, Chief Financial Officer, will participate in a fireside chat at 4:15 p.m. EDT. Wells Fargo 2020 Virtual Healthcare Conference on Thursday, September 10, 2020. Tassos Gianakakos, Chief Executive Officer, will participate in a fir

• MyoKardia Presents Results from Phase 3 EXPLORER-HCM Clinical Trial of Mavacamten for the Treatment of Obstructive Hypertrophic Cardiomyopathy

  8/29/2020

  EXPLORER-HCM Data Presented During Live Hot Line Session at ESC Congress 2020 with Simultaneous Publication in The Lancet

• MyoKardia and LianBio Form Strategic Partnership to Develop and Commercialize Mavacamten Together in Greater China

  8/11/2020

  Near-Term Focus on Pursuing Approval of Mavacamten for Obstructive HCM Innovative Model Focused on Long-Term Value Creation:  MyoKardia Receives Equity Position in Lian Cardiovascular and Tassos Gianakakos, MyoKardia’s CEO, to Join LianBio Board of Directors BRISBANE, Calif., Aug. 11, 2020 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq: MYOK) and LianBio announced today that they have entered into a strategic collaboration to develop and commercialize mavacamten in China and other Asian te

• Data from EXPLORER-HCM Study Selected for Virtual Late-Breaker Presentation at the European Society of Cardiology Congress 2020Virtual Analyst and Investor Event to Review Data Planned for 8:00 a.m. EDT on August 31

  8/10/2020

  MyoKardia, Inc. (Nasdaq: MYOK) today announced that the company will present 38-week data from its pivotal Phase 3 EXPLORER-HCM clinical trial during a late-breaker session at the upcoming European Society of Cardiology Congress 2020 (ESC Congress 2020).

• MyoKardia to Present at 2020 Wedbush PacGrow Healthcare Virtual Conference

  8/5/2020

  MyoKardia, Inc. announced that Jake Bauer, Chief Business Officer, will present at the 2020 Wedbush PacGrow Healthcare Virtual Conference on Tuesday, August 11, 2020 at 3:30 p.m. ET.

• MyoKardia Reports Second Quarter 2020 Financial Results

  8/4/2020

  MyoKardia, Inc. (Nasdaq: MYOK), today reported financial results for the second quarter ended June 30, 2020.

• MyoKardia Doses First Patient in Phase 3 VALOR-HCM Trial of MavacamtenVALOR-HCM Designed to Generate Direct Evidence of Improved Outcomes for People with HCM by Reducing the Need for Invasive Septal Reduction Therapy

  8/3/2020

  MyoKardia, Inc. (Nasdaq: MYOK) announced that the first patient has been dosed in the Phase 3 VALOR-HCM clinical trial.  VALOR-HCM will enroll individuals with obstructive hypertrophic cardiomyopathy (HCM) who have been referred for septal reduction therapy (SRT) and are refractory to current therapeutic options, including those who have severe symptoms (NYHA Class IV).  VALOR-HCM is designed to provide direct clinical evidence of mavacamten’

• MyoKardia to Report Second Quarter 2020 Financial Results on Tuesday, August 4, 2020

  7/28/2020

  MyoKardia, Inc. (Nasdaq: MYOK), today announced that it will report second quarter financial and operating results on Tuesday, August 4, 2020. Management will host a conference call and live audio webcast to discuss these results and provide a business update at 4:30 p.m. ET (1:30 p.m. PT).  Conference Call and Webcast Analysts and investors are invited to participate in the conference call by calling 844-494-0193 from the U.S. and Canada

• MyoKardia Announces Receipt of Breakthrough Therapy Designation from FDA for Mavacamten for the Treatment of Symptomatic, Obstructive Hypertrophic Cardiomyopathy

  7/23/2020

  MyoKardia, Inc. (Nasdaq: MYOK) today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to mavacamten, a novel, oral, allosteric modulator of cardiac myosin, for the treatment of symptomatic, obstructive hypertrophic cardiomyopathy (HCM

• MyoKardia and Fulcrum Therapeutics Announce Multi-Target Collaboration to Discover Novel Targeted Therapies for Genetic Cardiomyopathies

  7/21/2020

  Collaboration will Combine MyoKardia’s Leading Precision Cardiovascular R&D Platform with Fulcrum’s Proprietary Product Engine to Identify Targets that Modulate Gene Expression

• 

  MyoKardia: The Precision Cardiac Medicine Company with Diversity and Inclusion at its Heart

  7/7/2020

  Putting your employees and company culture first keeps the focus on inclusion and innovation, giving the company an incredible competitive advantage.

• MyoKardia Announces Appointment of Denelle J. Waynick as General Counsel and Corporate Secretary

  7/6/2020

  MyoKardia, Inc. (Nasdaq: MYOK) today announced the appointment of Denelle Waynick as General Counsel and Corporate Secretary. Ms. Waynick joins MyoKardia from UCB, Inc., bringing more than 25 years of domestic and international legal and business expertise in the healthcare and life-science industry. Cynthia Ladd, who has been leading MyoKardia’s legal function as General Counsel since January 2018, will be retiring this year. “Denelle is

• MyoKardia Announces Positive Data from Phase 2a Clinical Trial of Danicamtiv Presented at ESC’s HFA Discoveries with Simultaneous Publication in European Journal of Heart Failure

  6/22/2020

  MyoKardia, Inc. (Nasdaq: MYOK) today announced the presentation and publication of positive data from the company’s Phase 2a clinical trial of danicamtiv (formerly MYK-491) along with nonclinical data elucidating danicamtiv’s novel mechanism of action.

• MyoKardia Announces Danicamtiv Data Presentation at the European Society of Cardiology’s Virtual Heart Failure Association Discoveries

  6/19/2020

  -- MyoKardia to Host Conference Call at 8:30 a.m. ET on Monday, June 22, 2020 --

• MyoKardia to Present at Virtual BMO 2020 Prescriptions for Success Healthcare Conference

  6/16/2020

  MyoKardia, Inc. (Nasdaq: MYOK) today announced that Tassos Gianakakos, Chief Executive Officer, will participate in a fireside chat at the virtual BMO 2020 Prescriptions for Success Healthcare Conference on Tuesday, June 23 rd , 2020 at 10:30 a.m. ET. A webcast of the presentation will be available by visiting the Investors section of MyoKardia’s website at http://investors.myokardia.com. A replay of the webcast will be available on the Myo

• 

  How COVID-19 is Affecting Clinical Trials and Drug Supplies from Biotech Bay Companies

  6/5/2020

  Check out this article for the impacts that Biotech Bay companies are experiencing due to COVID-19.